Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
| Business Activity | PASS |
| Debt Ratio (0.60%) | FAIL |
| Cash Ratio (0.00%) | PASS |
| Receivables Ratio (0.25%) | PASS |
| Revenue Ratio (0.01%) | PASS |
| Overall | FAIL |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-08-04 | 1.86 | Pending | — |
| 2026-05-07 | 1.54 | 1.42 | -7.6% |
| 2026-02-12 | 1.40 | 1.48 | +5.5% |
| 2025-11-04 | 1.62 | 1.70 | +4.8% |
| 2025-08-05 | 1.61 | 1.76 | +9.2% |
| 2025-05-06 | 1.40 | 1.48 | +5.8% |
| 2025-02-13 | 1.36 | 1.40 | +2.8% |
| 2024-11-04 | 1.46 | 1.58 | +8.0% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2.3B | $601.0M | $939.0M | $1.6B | $822.0M | 1.42 |
| 2025-12-31 | $2.4B | $603.0M | $939.0M | $1.7B | $826.0M | 1.38 |
| 2025-09-30 | $2.4B | $721.0M | $1.1B | $1.7B | $936.0M | 1.63 |
| 2025-06-30 | $2.5B | $718.0M | $1.1B | $1.8B | $989.0M | 1.61 |
| 2025-03-31 | $2.2B | $602.0M | $946.0M | $1.6B | $812.0M | 1.34 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-05-13 | BISARO PAUL M. | Director | 2,000 | $151.8K |
| 2026-05-13 | D AMELIO FRANK A | Director | 6,650 | $501.3K |
| 2026-05-11 | MCCALLISTER MICHAEL B | Director | 3,000 | $233.3K |
| 2026-04-30 | ESCH KEVIN PH.D. | Officer | 259 | — |
| 2026-03-31 | SARBAUGH KEITH | Officer | 1,528 | — |
| 2026-03-09 | NORDEN GREGORY | Director | 1,213 | — |
| 2026-02-19 | ESCH KEVIN PH.D. | Officer | 102 | — |
| 2026-02-19 | ASHTON NICHOLAS | Officer | 750 | — |
| 2026-02-19 | DRISCOLL RIMMA | Officer | 454 | — |
| 2026-02-19 | BRANNAN JAMIE | Officer | 1,204 | — |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Blackrock Inc. | 35.6M | $2.9B | 0.1% |
| Vanguard Capital Management LLC | 26.1M | $2.1B | 0.1% |
| Vanguard Portfolio Management LLC | 24.0M | $1.9B | 0.1% |
| State Street Corporation | 19.3M | $1.6B | 0.0% |
| State Farm Mutual Automobile Insurance Co | 15.9M | $1.3B | 0.0% |
| Morgan Stanley | 14.1M | $1.2B | 0.0% |
| Geode Capital Management, LLC | 11.3M | $922.9M | 0.0% |
| Wellington Management Group, LLP | 10.2M | $825.4M | 0.0% |
| Nordea Investment Management AB | 5.9M | $477.0M | 0.0% |
| Northern Trust Corporation | 5.5M | $451.0M | 0.0% |
Buy
Hold
Sell
Strong Sell
$41.4B
10.37
0.863
17
$9.5B
$9.3B
+6.0%
256.0%
1.95
4.54
0.0%
14,500
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-08-04 | $1.86 | Pending | — |
| 2026-05-07 | $1.54 | $1.42 | -7.6% |
| 2026-02-12 | $1.40 | $1.48 | +5.5% |
| 2025-11-04 | $1.62 | $1.70 | +4.8% |
| 2025-08-05 | $1.61 | $1.76 | +9.2% |
| 2025-05-06 | $1.40 | $1.48 | +5.8% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($124.59, 17 analysts) | |||
| 10 | $828.30 | +$417.60 (50%) | 3.4R |
| 50 | $4,141.50 | +$2,088.00 (50%) | 3.4R |
| 100 | $8,283.00 | +$4,176.00 (50%) | 3.4R |
| To Fair Value ($150.00) | |||
| 10 | $828.30 | +$671.70 (81%) | 5.4R |
| 50 | $4,141.50 | +$3,358.50 (81%) | 5.4R |
| 100 | $8,283.00 | +$6,717.00 (81%) | 5.4R |
- Elevated short interest (4.54 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| PAHC | 0.508 |
| IBP | 0.457 |
| XZO | 0.457 |
| XLV | 0.440 |
| MOO | 0.439 |
| Ticker | Correlation |
|---|---|
| NAHO.AE | -0.188 |
| TIJARA.KW | -0.186 |
| EMPOWER.AE | -0.177 |
| NP | -0.169 |
| 5802.T | -0.157 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker’s recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.
Related Tickers
Similar in Healthcare
Also in TE500